Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARC II phase II trial of ANX776 retinal apoptosis imaging
ISRCTN10751859Phase 2Completed
- Sponsor
- University College London
- Start
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ANX776 in Glaucoma, age-related macular degeneration (AMD), optic neuritis (ON) and 1 more (5 cohorts), sponsored by University College London. Primary endpoint: DARC count at 4 hours. Started Feb 2017; status: completed.
02
Drugs
ANX776
03
Conditions
Glaucomaage-related macular degeneration (AMD)optic neuritis (ON)Down syndrome
Beyond the preview
Go deeper on ISRCTN10751859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10751859.